Imperial College London
Portrait Picture

DrGeorgiosNteliopoulos

Faculty of Medicine, Department of Surgery & Cancer

Research Associate Biomarker
 
 
 
//

Contact

 

georgios.nteliopoulos04

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Page:2021:10.1200/PO.20.00522,
author = {Page, K and Martinson, LJ and Fernandez-Garcia, D and Hills, A and Gleason, KLT and Gray, MC and Rushton, AJ and Nteliopoulos, G and Hastings, RK and Goddard, K and Ions, C and Parmar, V and Primrose, L and Openshaw, MR and Guttery, DS and Palmieri, C and Ali, S and Stebbing, J and Coombes, RC and Shaw, JA},
doi = {10.1200/PO.20.00522},
journal = {JCO Precision Oncology},
pages = {1768--1776},
title = {Circulating tumor DNA profiling from breast cancer screening through to metastatic disease},
url = {http://dx.doi.org/10.1200/PO.20.00522},
volume = {5},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: We investigated the utility of the Oncomine Breast cfDNA Assay for detecting circulating tumor DNA (ctDNA) in women from a breast screening population, including healthy women with no abnormality detected by mammogram, and women on follow-up through to advanced breast cancer. MATERIALS AND METHODS: Blood samples were taken from 373 women (127 healthy controls recruited through breast screening, 28 ductal carcinoma in situ, 60 primary breast cancers, 47 primary breast cancer on follow-up, and 111 metastatic breast cancers [MBC]) to recover plasma and germline DNA for analysis with the Oncomine Breast cfDNA Assay on the Ion S5 platform. RESULTS: One hundred sixteen of 373 plasma samples had one or more somatic variants detected across eight of the 10 genes and were called ctDNA-positive; MBC had the highest proportion of ctDNA-positive samples (61; 55%) and healthy controls the lowest (20; 15.7%). ESR1, TP53, and PIK3CA mutations account for 93% of all variants detected and predict poor overall survival in MBC (hazard ratio = 3.461; 95% CI, 1.866 to 6.42; P = .001). Patients with MBC had higher plasma cell-free DNA levels, higher variant allele frequencies, and more polyclonal variants, notably in ESR1 than in all other groups. Only 15 individuals had evidence of potential clonal hematopoiesis of indeterminate potential mutations. CONCLUSION: We were able detect ctDNA across the breast cancer spectrum, notably in MBC where variants in ESR1, TP53, and PIK3CA predicted poor overall survival. The assay could be used to monitor emergence of resistance mutations such as in ESR1 that herald resistance to aromatase inhibitors to tailor adjuvant therapies. However, we suggest caution is needed when interpreting results from a single plasma sample as variants were also detected in a small proportion of HCs.
AU  - Page,K
AU  - Martinson,LJ
AU  - Fernandez-Garcia,D
AU  - Hills,A
AU  - Gleason,KLT
AU  - Gray,MC
AU  - Rushton,AJ
AU  - Nteliopoulos,G
AU  - Hastings,RK
AU  - Goddard,K
AU  - Ions,C
AU  - Parmar,V
AU  - Primrose,L
AU  - Openshaw,MR
AU  - Guttery,DS
AU  - Palmieri,C
AU  - Ali,S
AU  - Stebbing,J
AU  - Coombes,RC
AU  - Shaw,JA
DO  - 10.1200/PO.20.00522
EP  - 1776
PY  - 2021///
SN  - 2473-4284
SP  - 1768
TI  - Circulating tumor DNA profiling from breast cancer screening through to metastatic disease
T2  - JCO Precision Oncology
UR  - http://dx.doi.org/10.1200/PO.20.00522
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34849446
UR  - http://hdl.handle.net/10044/1/93071
VL  - 5
ER  -
Download